HER2 immunohistochemistry and fluorescence in situ hybridization
Selected primary breast cancers and brain metastases with available tumor tissue were subjected to re-assessment of HER2 status using IHC (anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody kit, Ventana Medical Systems) and/or FISH. FISH for HER2 was performed on 4 μm-thick sections using the Food and Drug Administration (FDA)-approved Vysis PathVysion HER-2 DNA Probe Kit (Abbott Molecular Inc, Des Plaines IL, USA) according to manufacturer's instructions. Normal tissues including vessels, fibroblasts, lymphocytes or nontumor breast tissues served as internal controls. Tumor tissues were evaluated using a 100× objective.
Targeted capture massively parallel sequencing
Tumor and normal DNA samples were subjected to targeted capture massively parallel sequencing at the Memorial Sloan Kettering Cancer Center (MSKCC) Integrated Genomics Operation (IGO). In this study, we employed a previously described customized breast cancer panel targeting all exons of 254 genes recurrently mutated in breast cancer and DNA repair-related genes (Supplementary Table 1 ) using custom oligonucleotides (NimblegenSeqCap) as described [2, 3] . Barcoded sequence libraries were prepared (New England Biolabs, KapaBiosystems) using 50 ng-250 ng of DNA. Massive parallel sequencing was performed on an Illumina HiSeq2000 (San Diego, CA), and bioinformatics analyses were performed as previously described [2, 3] . Allele-specific copy number alterations (CNAs) and loss of heterozygosity (LOH) of the wild-type allele in genes harboring a somatic mutation were inferred from massively parallel sequencing data using FACETS [4] .
Validation of mutations by amplicon sequencing
Selected mutations found by targeted sequencing (n = 108, consisting of 104 unique mutations) were subjected to orthogonal validation using amplicon resequencing in all samples for a given patient, where genomic DNA was available in the MSKCC IGO (Supplementary Table 2 ). For amplicon resequencing, 5 ng of genomic DNA was amplified with primers specific for a given mutation using the AmpliTaq gold 360 master mix (Invitrogen Life Science Technologies). Amplicons were bead-purified, quantified and pooled. Pooled amplicons were subjected to standard protocol of Illumina library preparation sequencing (MiSeq). Reads were aligned to the reference human genome GRCh37 using BWA (v0.6.2) [5] , and local realignment was performed using GATK (v3.1.1) [6] . Pileup files were generated using SAMtools [7] . Mutations with > 1% of mutant allele frequency (MAF) and covered by at least 50 reads were considered validated. The validation rate of the somatic mutations with sufficient coverage was 93% (100/108). False-positive variants were excluded from further analyses. Given the high validation rate, untested mutations were included in further analyses. In addition, of the 70 mutations that were not detected in a sample of a given case based on the initial targeted sequencing, 11 (16%) were subsequently detected by amplicon sequencing and were included in the analyses, with the remaining confirmed to be genuinely absent even at a median depth of 10564× (range 272×-49532×).
Inference of cancer cell fraction (CCF)
ABSOLUTE (v1.0.6) [8] was used to infer the cancer cell fraction (CCF) of each mutation using the number of reads supporting the reference and the alternate alleles and the segmented Log 2 ratio from targeted capture massively parallel sequencing. A mutation was classified as clonal if its probability of being clonal was > 50% [9] or if the lower bound of the 95% confidence interval of its CCF was > 90%. Mutations that did not meet the above criteria were considered subclonal.
Identification of potentially pathogenic mutations
A combination of MutationTaster [10] , CHASM (breast) [11] and FATHMM [12] was used to define the potential functional effect of each missense somatic single nucleotide variant (SNV). Missense SNVs defined as non-deleterious/passenger by both MutationTaster [10] and CHASM (breast) [11] , a combination of mutation function predictors shown to have a high negative predictive value [13] , were considered likely passenger alterations. The remaining missense SNVs were defined as likely pathogenic if they were predicted to be "driver" and/ or "cancer" by CHASM (breast classifier) and/ or FATHMM [12] , respectively. Frameshift, splice-site and nonsense mutations were considered likely pathogenic if they were targeted by loss of the wild-type allele or affected haploinsufficient genes [14] . SNVs, including missense and nonsense SNVs, affecting hotspot residues [15] were also considered likely pathogenic and were separately annotated. Mutations were also annotated if they affected genes included in the cancer gene lists described by Kandoth et al. (127 significantly mutated genes) [16] , the Cancer Gene Census [17] or Lawrence et al. (Cancer5000-S gene set) [18] . Mutations that were neither likely pathogenic nor likely passenger were considered of indeterminate pathogenicity.
Actionable somatic genetic alterations
The DGIdb database [19] defines a list of 402 known and potential actionable genes (Supplementary Table 5 ). The clinically actionability of DGIdb is defined based on Bader Lab Genes, Caris Molecular Intelligence, Foundation One Genes, GO, Guide To Pharmacology Genes, Hopkins Groom, MSK-Impact, Russ Lampel and dGene.
OncoKB [20] is a comprehensive and curated precision oncology database with more than 3,000 unique mutations, fusions, and copy number alterations in 418 cancer-associated genes. It annotates the biologic and oncogenic effects, and provides the level of evidence that a specific molecular alteration is predictive of drug response on the basis of US Food and Drug Administration labeling, National Comprehensive Cancer Network guidelines, disease-focused expert group recommendations, and scientific literature.
Phylogenetic tree construction
A maximum parsimony tree was built for each case using binary presence/absence matrices based on the repertoire of somatic non-synonymous and synonymous somatic mutations, gene amplifications and homozygous deletions in the biopsies of the primary tumor and the metastatic lesion, as described by Murugaesu et al. [21] . A starting tree was constructed using the Neighbor-joining method and Hamming distance and optimized using the parsimony ratchet method implemented in the R package Phangorn [22] . Trees were rooted at the hypothetical normal where all somatic alterations are absent. Branch lengths were determined according to the ACCTRAN criterion as implemented in the Phangorn package and were drawn to scale.
Supplementary Figure 1:
The mutational signatures of Case 14 were derived from the analyses of the somatic mutations in the primary breast cancer (A), mutations in the metastasis (B), mutations private to the primary (C), mutations private to the metastasis (D) and mutations shared between the primary and the metastasis (E). Below the graphs is the inferred contribution of the different signatures as defined by deconstructSigs. CACNA1C_A317V  TTCTTTCTCTGCCCACATCTC  GGCAAAGTTGTCAAAGTTGGT   CACNA1C_E1948K  TGCTTTCCGGGGGTG  GCGGTGCATTTACCTAGTGAG   CACNA1E_L1575V  TGAGGGATAAATACACAAATACTAGTG  TCAGAGAGGATTTGCTGGTACC   CACNA1E_L2058V  TCGGGATAAGCGTTCAAATT  GTAAGTGCATCAGGGCAGG   CDH1_Q23  GGAGGGGCGGCGCTGTT  TCACCTCTGCCCAGGACGC   CDH1_Q346  TGTGTTGGGCTGGGCTAG  GTGGTGGGATTGAAGATCG   CEP164_S1123C  TCCTGCTCCAGCCTGTCC  CTTGATGCCTGGTGGGTC   CHD4_D314Y  CGGAGTTTCTTGCGGCT  GTCCCCAGTGAGAGAGTACTCC   CHD4_E138D  AAAGGGCAGTAAGGTGTCTAGGA  GTGAGGGCAGCGACTATACTC   CHD6_K2587T  TCCAGGAGATACTCCTGGGAT  CTATCAAGCACAACGAAAAGTGG   CHD6_L1643H  ATCAGGCAGGCTGAGATGAT  GATGCCTATAGAAACTATGCCCAG   CHEK2_K298T  TTCCTGAGTTTAAAAATCATCAATCT  AAAACATTCAGACAATCACTATCTTTG   CUBN_E1520K  GTGAAGTTCAAGAGAACACGATG  CCAGGTAATGGATTATTTTCGAG   DEPTOR_P325L  TGGATAGAGGACTTGGAAGTGC  ATAAGCTACCCATTGACACATGG   DOCK11_S1189F  TTTCAGAACCAACAAGCCAA  CATATAGCATATGACCCCAATTCC   EPPK1_-1464  AGGGCCGCAGCCCTC  GTTGCCACTGCCCTCAGA   EPPK1_M2050I  GGAACAGCAGCCAGCC  TCGACCCACAGCACCAC   EPPK1_T568P  GAGGCCAGGCTGCCC  GACCCTCTCCGTGGAGAAG   ERBB2_D769Y  CCAGGGCATCTGGATCC  CATATCTCCCCAAACCCCA   ERBB2_P1227S  CCCCGAGTACTTGACACCC  GGCCTTCTGGTTCACACTG   ERBB3_M1114I  CAGTCTCTCTACACCCAATGCC  GGGAGAGTGGGGTAACAGG   ERBB3_V1101I  GGAGTCTGCAGTTTCTGGGA  GAATGGTAGGCGCTATCTCC   ERCC2_R196Q  AGCAAGCAACAGACAGACATG  GCCCATGGGCGTGAG   FANCD2_E14Q  TAACTTCTGTTTCCCGATTTTGC  AAGCAGGAACTTTATATCTCTCACATG   FANCD2_Q802H  AACTCAAAGATCTTGCTTTTCATAGAC  TTCATCTCAGGTGATGTTTCCT   FANCE_L369R  CTCTCAGACCTCGGTCTCCT  TGGGAATCCCCTCTCTCAA   FGFR2_D759H  GTGTGTGTAAAACACTACGCATGTC  TTCAAGGAAATCCATTTTTCCC   GATA3_P426P?  TCCCCAAGAACAGCTCGTT  ATGCAAGTCGAAAGGGACTG   HECW1_D448A  CCAGCTGAGGAAGCAGCA  GCTGGCTGGGGCTTCA   HIST1H3B_D78H  CAAAGGTTTGTGTCCTCAAAGAG  GGGCACTGTGGCTCTGC   HIST1H3B_E134Q  AAATTATCACAGCTACTTTCGTTGG  CTTGGTAGGGCTCTTTGAGGA   HRNR_P573L  ATGACCCGAGCTAGATCCG  TCTCCTAGCCCTAGCCGTG   INPP4B_Q498H  TTGAGAGGCAAGCGATATACAA  TTGTCAGGAGTGCTCTTTTAGC   KMT2C_D4530H  GGAAGCAGCTGACCAATTGT  TAAGGACAAAACTATGCTTTGCC   KMT2C_K2769N  TTTTGTTTTCTTGTTCCTTTTTTTT  ATAATTTGGAAACTAATGATCCCAAC   KMT2C_R41S   GACAGCTCCGGCCCG  GAGCGTGGAGCAGCCG  KMT2D_E1861K  ACCCTTATACACAAAGAGGTACGG  GTGGCCATGACCCATCCT  LAMA5_A907T  CCTGAGGCCTGGGCCTTCAA  TACCTCCCGGACCTGCACCA  MACF1_G3580D  GGGATCAGAGACTCCTCATTCC  ATAAGTAGACTGGAACTTGGTGGC  MACF1_L617V  TCCTACCAAGCCAGCAGTAAA  GGATTCTGAAGGCTACGCAC  MAP2K4_S303R  CATTTGCCTATTCCTTGAGTGTAA  ATTATAGTTCTTAACGAACGGGGA  MAP2K6_L229H  CCATCCCCAGAGACTATTGAG  TCATTACCCACAACCTCATAGTTC  MDN1_-585  AGCAAAAAATCCTAGCCTCCTT  GTTTCTCCCTCTTGTGGCC  MED12_E1740Q  AACAGTCCGAGTGGACCG  CCCGGTTTGTCAGTTTTGG  MED12_P561S  AAAAGTCAGTTCTACAATTTGTTCTGT  TAGGCAGAGGTAACTAGAGAGTGGTAG  MLH1_R100Q  TCTGGATATTGTATGTGAAAGGTTC  CAAGTAAAAGGTACCAAACCTTATTT  NBEAL2_T1422A  TCCTTCGCCACTGGATG  TGTACCAGAAGTGTCCTCCCTT  NBN_E510A  TTCTGCAGCATGAGATTTACTGG  TCATGCAAATCAGCAAGAATAGA  NBPF1_E168K  ACCACCCATTACTTGCTCCC  ACATAGATGTTCATGTCTCTGTGCA  NBPF1_Q974  GGAACTTCCATAGGGCAGG  TAGCCATGAAATGTAGCTGGG  NCOA3_Q1358  CTTTGGTCGAGTGTCTAGTCCTC  TGGACTTCTGGGACTAGGATGT  NEB_R7478Q  GCATGCCTTGGCAATG  AAAAAAAGCCTCTCTCTTGAGTAAAC  PARP1_D217H  TGTCGAAAGGAGACACAGAGC  CACCGCAAGTCATTGGGT  PAXIP1_L537F  GGTGGAACCTGATGCTGC  GCTGCAGCAGCACCAG  PIK3CA_E542K  TTATTTTATTTTACAGAGTAACA  TTCAGTTATTTTTTCTGTAATAAA  PIK3CA_H1047R  CAATCTTTTGATGACATTGCATACA  CCAGAGTGAGCTTTCATTTTCTC  PIK3CA_K111T  GAAAGGGAAGAATTTTTTGATGAA  TTAGACAGAAATATTTTAGAAAGGGAC  PIK3CB_S769  AGGCTGACAGCTGGCC  GCCAAAGGGAAGGAGGC  PIK3R1_D529H  AAACCATAGTGAAACTTTTCATAAACT  CGTTTGTCAATTTCTCGATACTCA  POLD1_E795Q  CCGATTCGGCGTGTC  CTTCACACTGTGGCTTTTGTG  POLH_R105G  CAGACAATCTCAAGGTTGCCT  GAGATAGGCTGACCTTGTAGCTTT  PRKCA_K91T  GCTCGTATGTTAAATCATGTCTATTCT  TCCCATTAACAGTAAGTGCCAA  PRKD1_D893N  AGTTCCACAGTGTTTTGACAGATT  CATCACCCATGAAAGTGATGAC  RAF1_D19Y  GAAGGATCTGTGAGTTTGCCA  TTATTTGTGTTTCTTACCAGGTTTAAG  RAF1_D23H  TTGCTTGTCTTAGAAGGATCTGTG  CTTACCAGGTTTAAGAATTGTTTAAGC  RELN_E1824Q  TAGTAGTAATGTTGGGAAGGAGAATCT  TGGACCCTATTGTGTTCCTGT  RELN_E701G  GACTTCAGCACCACGGATAGA  CAAAGTAGATTCGAGAATCTCCG  RELN_L1854R  GCACAGGGGAGAATTCTCTTG  TATAAAATCAAAGGGATACAATTTTGC  RELN_N290T  AGGCATATAGGAGAGTAGAAC  TTTTAACCTTGAAATTTATTGTTA  RICTOR_D861Y  AGAAGCAGAATATACAAAAACTCAGAA  TCCTCTAGGAATACAACTCCAAA  RPGR_E709K  TCCTCTTCTTCTCCTTCTCCATG  GAAGGGGGAGAAAGACAAGG  RPTOR_E163Q  AGTCAAGAAGCTCTGCACGTC  GATGGGCAGGACCTGCTC  SOS1_D169H  CTGGAGATATTCCCCAACACA  TGCAGACATTTTAAAGCTGGTT  SOS1_R1041C  TCTGTTTCACTTTCAGGGATCC  GAAAAACTTTCCTTTCTACTACAGTGT  SRCAP_E2638K  TTCTGCACCCAGCCTGAC  TCAGCCTCCAGTGGCTCC  SRCAP_H2925Q  CTGACCCAGTCCCTGGGC  CCCCTGCAGAGGAAATGGTC  STAT1_L312F  TAAACCCTTGTAAATCATCTGAATTAA  AAAGTTGGAGGAATTGGAACAG  TENM1_D477H  TAAAACGCCAGATACCAAGGTC  AAAAAGTAGTGGCTCATCTTCATGT  TENM1_S1855L  AATTTTCCCATCAGCCCAA  CGAAAATTCACCCTTCGAATT  TOP2A_D524N  AGACATGCTTAATTTAGTTGAACAATC  TTTTTGGTATATGTCCATTTCAGA  TOP2A_D526N  GACATGCTTAATTTAGTTGAACAATCT  TTTTTTTGGTATATGTCCATTTCAGA  TOP2A_E1226K  CACCTTGGCCCCCAA  CGATGCTTTTTTTGGTATATGTCC  TOP2A_V983G  AATTGAAACGTGTACATCTCACAAAA  TGTTGAATGGCACCGAGAAG  TP53_H214R  GCTCACCTGGAGGGCC  CCTCACTGATTGCTCTTAGGTCT  TP53_Q331  AATGCCCCAATTGCAGGTA  TTTATCACCTTTCCTTGCCTCTT  TP53_R248W  GAGGCAAGCAGAGGCTG  GGCCTCATCTTGGGCC  TP53_Y236C  TGCAGGGTGGCAAGTG  TCCCCTGCTTGCCACA  TYK2_E437K  ACCCTTGGCGGTGGC  GGAGCTGAGCTTGCCTTC  TYK2_S134L  CCACAAATAGTCTTGCCACCC  GTCCCTCCTTCCTGCAGG  UBR4_E1114  TCAGTCTCAGCAGCCATCTTAG  TTTCTACCATAGCCCATTGCC  UBR4_K1150T  GCATCTCTGGGCAGGC  AGTCTGCAGTCCATCTACACCC  WDFY3_K2603N  TTCAGAATAAAGAAACATGATAAAACA  TGGAACAGTGAATTTATCCCTTG  WDFY3_Q2808H  AGATAATGATGTTTTAAAAGGTGACAT  TTTCTTAAACAGGAGAAACTCCTGC  ZFHX3_L357R  GAGAGCTTCCTCCCCTTCC  AAGAACATCTCCGCTATCATCC  ZFHX3_Q2952E  AGTCCAATGTCATTGCCCA  AAGCCTTGCAGATCCCTG  ZFHX4_L686P  TACAAATATCAGCAGACCCTGG  CTGCATATGAATACTGAGGTTGC  ZFP36L1_D304N  AGCCCCATGCTAGGGG  CTTTAGCTTTGCTGGGTTTCC  ZNF703_S389W  AAGCCCCCCAGCTCCA  CGGGTGCCCGGGGTA 
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